Prelude Therapeutics PRLD director gets 121,285 options at $1.39

Prelude Therapeutics (PRLD) reported a director equity grant.

Rhea-AI Filing Summary

Prelude Therapeutics (PRLD) reported a director equity grant. On 11/05/2025, the reporting person received stock options for 121,285 shares at an exercise price of $1.39 per share. The options vest over one year, at one‑twelfth each month, and expire on 11/04/2035. The filing was made by one reporting person with direct ownership.

Insider Trade Summary

Grant/Award: 121,285 shares

Grant/Award 1 txn

Insider Sandor Victor

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	121,285	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 121,285 contracts (Direct)

Footnotes (1)

1. F1. The option award vests over a one year period equally one-twelfth per month, subject to Reporting Person's continued service to the Company on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prelude Therapeutics (PRLD) disclose in this Form 4?

A director was granted 121,285 stock options at an exercise price of $1.39 on 11/05/2025.

What is the exercise price and expiration of the PRLD options?

The exercise price is $1.39 per share, and the options expire on 11/04/2035.

How do the PRLD director options vest?

They vest over one year, one‑twelfth per month, subject to continued service.

Who filed this PRLD Form 4?

It was filed by one reporting person with direct ownership.

What class of security underlies the options?

The options are for Common Stock of Prelude Therapeutics.

What was the number of derivative securities beneficially owned after the transaction?

The filing reports 121,285 derivative securities beneficially owned following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 04:28 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandor Victor

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DE 19805

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$1.39	11/05/2025		A		121,285		(1)	11/04/2035	Common Stock	121,285	$0.00	121,285	D

Explanation of Responses:

1. The option award vests over a one year period equally one-twelfth per month, subject to Reporting Person's continued service to the Company on each vesting date.

Remarks:

	/s/ Krishna Vaddi, Attorney-in-Fact	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.